WSJ Opinion: The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
WSJ Opinion: The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this say about the Trump Administration's approach toward drug innovation?
28:21